INFLUENCE OF GUT MICROBES AND INFLAMMATION ON BRAIN FUNCTION AND BEHAVIOUR IN AUTISM
With
Angela Renata Jiménez Perez,
PhD Candidate,
Gut-Brain Axis Laboratory, RMIT University
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | August 2026
Third-year PhD candidate Angela Jimenez is part of the Gut-Brain Axis Laboratory at RMIT University in Melbourne, Australia. Angela holds a bachelor’s degree in neuroscience (Honours) from the National Autonomous University of Mexico (UNAM), and her doctoral research is currently supported by the RMIT–Mexico International Scholarship program.
Angela’s project focuses on describing how gut microbes and inflammation influence brain function and behaviour in autism. Using a mouse model that carries an autism-associated gene variant, she investigates how inflammatory challenges alter behaviour and brain function. Her work has been presented at both national and international forums, including the Australasian Neuroscience Society (ANS) annual meeting in 2025 and the FENS Forum 2026 in Barcelona.
A central aspect of her work explores how metabolites produced by bacteria in the gut can influence neurobiological responses, with the long-term aim of identifying microbiota-targeted therapeutic strategies for individuals with high-support needs autism.
Angela’s broader scientific objective is to advance mechanistic understanding of how other systems, particularly the immune system and microbiome, contribute to behavioural outcomes in neurodevelopmental conditions. She aims to bridge fundamental neurobiology with translational approaches that can lead to future therapeutic development.
Source: Supplied
-
Biomarkers for early sepsis detection
Dr Gabrielle Briggs is a biomedical scientist dedicated to finding smarter, faster ways to diagnose and treat life threatening complications in critically ill patients. Dr Briggs established a research laboratory embedded within the John Hunter Hospital – one of the busiest major trauma centres in NSW. Dr Briggs works alongside surgeons, intensivists, and pathologists to turn complex clinical problems into practical research solutions. Her work spans two major programs: developing a rapid diagnostic test to detect bacterial infections in blood before sepsis takes hold, and exploring mitochondrial transplantation as a novel therapy to rescue injured tissues after trauma and ischaemia.
-
Investigating invasive lobular carcinoma and metaplastic breast cancer sub-types
Assoc Prof McCart Reed is the scientific lead on an MRFF-funded (Medical Research Future Fund) genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, ‘Q-IMPROvE’. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.
-
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
